Industry updates from the field of stem cell research and regenerative medicine in May 2022-Reference-Cited by-同舟云学术

Industry updates from the field of stem cell research and regenerative medicine in May 2022

Published:2022-09 Issue:9 Volume:17 Page:597-606
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Ilic Dusko¹^ORCID,Liovic Mirjana²^ORCID

Affiliation:

1. Department of Women & Children's Health, Stem Cell Laboratories, Guy's Assisted Conception Unit, Faculty of Life Sciences & Medicine, King's College London, London, SE1 9RT, UK

2. Medical Center for Molecular Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia

Abstract

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in May 2022.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2022-0104

Reference39 articles.

1. Be Biopharma. Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines (2022). www.be.bio/blog/be-bio-and-resilience-announce-strategic-collaboration-to-manufacture-engineered-b-cells-a-new-class-of-cellular-medicines/

2. Gilead Sciences. Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation (2022). https://investors.gilead.com/node/39826/pdf

3. Umoja Biopharma. Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer (2022). www.umoja-biopharma.com/news/umoja-biopharma-and-lupagen-announce-new-collaboration-to-improve-patient-experience-and-access-to-next-generation-in-vivo-therapeutics-for-cancer%EF%BF%BC/

4. Evotec. Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a ‘functional cure’ for diabetes (2022). www.evotec.com/f/8933e39b2c9c6de467ffa7c93d6daf26.pdf

5. BusinessWire. Accelerated Biosciences and Pluristyx Announce Availability of Human Trophoblast Stem Cell (hTSC) Derived iPSCs (2022). www.businesswire.com/news/home/20220504005149/en/